Intervention Maps · Chronic low back pain · Spinal cord stimulation
Spinal cord stimulation for persistent or hard-to-treat low back pain
This page is about an implanted stimulator considered for persistent or hard-to-treat low back pain. It is not a first-line treatment for ordinary chronic back pain, and it is not the same decision as disc or stenosis surgery.
Bottom line
Spinal cord stimulation is an implant consideration for persistent or hard-to-treat low back pain, not ordinary first-line care. A meaningful six-month benefit over placebo has not been established. The Cochrane review includes 13 trials and 699 people overall; its moderate-certainty six-month placebo-controlled evidence comes from one trial of 50 people and found no meaningful advantage. Newer open-label comparisons with medical management have reported larger benefits, but they were not blinded in the same way and do not answer the same question. Device harms including infection and explant occur.
What it is
An implanted device that delivers electrical stimulation to the spinal cord through leads placed in the epidural space, with a pulse generator under the skin. Trial stimulation periods are common before a permanent implant.
What taking part usually involves
Specialist assessment, a trial phase, implantation if the trial is judged successful, and ongoing device management. Infection, lead problems, revision, and explant are part of the real-world burden. This is not TENS.
What this is commonly confused with
A proven six-month placebo benefit. A newer open-label study that “updates away” older placebo evidence. Ordinary back surgery. A first-line nonspecific chronic-back-pain treatment.
What the evidence shows
The Cochrane review includes 13 trials and 699 people overall. That number describes the whole review.
Its moderate-certainty six-month placebo-controlled evidence comes from one crossover trial of 50 people. That trial found no meaningful advantage in pain, function, or quality of life. The review does not support spinal cord stimulation for low back pain outside a randomised placebo-controlled trial.
Newer studies comparing stimulation with conventional medical management have reported much larger benefits, but those studies were not blinded in the same way. They therefore do not answer the same question as a placebo-controlled trial.
Device-related serious harms, including infection and explant, occur.
Who was studied, expectations, and limits
Population and context studied: people with persistent or hard-to-treat low back pain, often after other care, sometimes after prior spine surgery and sometimes not, being considered for an implant.
That is the implant-consideration context, not a personal implant recommendation.
Realistic expectation: a six-month benefit over placebo is not established; open-label comparisons with medical management have reported larger effects, but those results cannot be interpreted in the same way as blinded placebo-controlled evidence. Limits: not TENS; not discectomy; not stenosis decompression.
Evidence consulted Open sources
Key sources used to prepare this answer. This is not a citation for every sentence.
- Traeger et al. Spinal cord stimulation for low back pain (Cochrane, 2023)
- North et al. SOLIS: SCS plus conventional medical management (Reg Anesth Pain Med, 2025) · later open-label comparison
- Eldabe et al. Network meta-analysis of SCS for chronic pain (Reg Anesth Pain Med, 2026) · companion synthesis
← Back to Chronic low back pain · find this again later from “What are you trying to figure out?”